SCHEMBL14949575

SCHEMBL14949575

Cc1ccc2c(Oc3cccc(-c4nnc(Nc5cccc(C(F)(F)F)c5)[nH]4)c3)ccnc2c1

nearest known ligand 0.43

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
BRAF P15056 7/20 0.43
KDR P35968 6/20 0.43
MAPK14 Q16539 3/20 0.43
TNNI3K Q59H18 2/20 0.43
RAF1 P04049 1/20 0.41
GAK O14976 1/20 0.39
ABCG2 Q9UNQ0 2/20 0.39
HTT P42858 1/20 0.38
GSK3A P49840 1/20 0.38
GSK3B P49841 1/20 0.38
EGFR P00533 1/20 0.38
AXL P30530 1/20 0.37
PHGDH O43175 1/20 0.37
PTK6 Q13882 1/20 0.36
AURKA O14965 1/20 0.36
MET P08581 1/20 0.36
PIK3CA P42336 1/20 0.36
TEK Q02763 1/20 0.36
AURKB Q96GD4 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL12336458 0.93 BRAF (0.43) BRAFKDRMAPK14TNNI3KRAF1
SCHEMBL12336578 0.93 BRAF (0.46) BRAFKDRMAPK14TNNI3KRAF1
SCHEMBL14949561 0.92 BRAF (0.48) BRAFKDRMAPK14TNNI3KRAF1
SCHEMBL12336249 0.91 GSK3A (0.49) BRAFKDRMAPK14TNNI3KRAF1
SCHEMBL12336445 0.91 BRAF (0.46) BRAFKDRMAPK14TNNI3KRAF1
SCHEMBL14949367 0.90 KDR (0.42) KDREGFRAXLMETTEK
SCHEMBL12336457 0.90 BRAF (0.43) BRAFKDRMAPK14TNNI3KRAF1
SCHEMBL12336272 0.90 BRAF (0.54) BRAFKDRMAPK14TNNI3KRAF1
SCHEMBL12336459 0.89 BRAF (0.45) BRAFKDRMAPK14TNNI3KRAF1
SCHEMBL12336454 0.86 GAK (0.51) BRAFKDRMAPK14TNNI3KRAF1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-9212151-B2 Heterocyclic compounds useful for kinase inhibition AMITECH THERAPEUTIC SOLUTIONS, INC. (US) 2015-12-15 US disclosed
US-20150158828-A1 Heterocyclic Compounds Useful for Kinase Inhibition AMITECH THERAPEUTIC SOLUTIONS, INC. 2015-06-11 US disclosed
US-8957216-B2 Heterocyclic compounds useful for kinase inhibition AMITECH THERAPEUTIC SOLUTIONS, INC. (US) 2015-02-17 US disclosed
US-20130123284-A1 HETEROCYCLIC COMPOUNDS USEFUL FOR KINASE INHIBITION AMITECH THERAPEUTIC SOLUTIONS INC (US) 2013-05-16 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20130123284-A1 HETEROCYCLIC COMPOUNDS USEFUL FOR KINASE INHIBITION MAP4K2, MAP3K20, MAP3K19 BRAF 39/4885KDR 533/4885MAPK14 90/4885
US-20150158828-A1 Heterocyclic Compounds Useful for Kinase Inhibition MAP4K2, MAP3K20, MAP3K19 BRAF 39/4885KDR 533/4885MAPK14 90/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.